BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9531875)

  • 1. Luteinizing hormone increases estradiol secretion but has no effect on progesterone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-releasing hormone agonist and follicle-stimulating hormone.
    Adonakis G; Deshpande N; Yates RW; Fleming R
    Fertil Steril; 1998 Mar; 69(3):450-3. PubMed ID: 9531875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of follicular growth and production of a normal hormonal milieu in spite of using a constant low dose of luteinizing hormone in women with hypogonadotrophic hypogonadism.
    Shoham Z; Howles CM; Zalel Y; Weissman A; Insler V
    Hum Reprod; 1994 Mar; 9(3):431-6. PubMed ID: 7516348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin requirements of the developing follicle.
    Thompson KA; LaPolt PS; River J; Henderson G; Dahl KD; Meldrum DR
    Fertil Steril; 1995 Feb; 63(2):273-6. PubMed ID: 7843430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of concentration of circulating luteinizing hormone in late-follicle phase on the outcome of in vitro fertilization for normogonadotrophic women].
    Sun H; Hu Y; Wang B; Chen Q; Zhang N; Chen H; Wang J; Xu Z
    Zhonghua Nan Ke Xue; 2004 Dec; 10(12):912-5. PubMed ID: 15638021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the "sweet spot" for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles.
    Werner MD; Forman EJ; Hong KH; Franasiak JM; Molinaro TA; Scott RT
    Fertil Steril; 2014 Nov; 102(5):1312-7. PubMed ID: 25150393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
    Younis JS; Matilsky M; Radin O; Ben-Ami M
    Fertil Steril; 2001 Aug; 76(2):294-9. PubMed ID: 11476775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different follicle-stimulating hormone and luteinizing hormone ratios for ovulation induction during in vitro fertilization.
    Tepper R; Tadir Y; Kaplan-Kraicer R; Amit S; Pinkas H; Ovadia J
    Int J Fertil; 1992; 37(6):335-8. PubMed ID: 1360452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon).
    de Jong D; Macklon NS; Eijkemans MJ; Mannaerts BM; Coelingh Bennink HJ; Fauser BC;
    Fertil Steril; 2001 Apr; 75(4):688-93. PubMed ID: 11287020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of the ratio in follicle-stimulating hormone and luteinizing hormone in induction of multiple follicular growth.
    Bernardus RE; Jones GS; Acosta AA; Garcia JE; Liu HC; Jones DL; Rosenwaks Z
    Fertil Steril; 1985 Mar; 43(3):373-8. PubMed ID: 3920087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J; Creus M; Fábregues F; Carmona F; Casamitjana R; Peñarrubia J; Rivera F; Vanrell JA
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation.
    Weissman A; Loumaye E; Shoham Z
    Hum Reprod; 1996 May; 11(5):943-9. PubMed ID: 8671368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone.
    Esposito MA; Barnhart KT; Coutifaris C; Patrizio P
    Fertil Steril; 2001 Mar; 75(3):519-24. PubMed ID: 11239535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.